SCHEMBL4010690

SCHEMBL4010690

O=C(NC1CCCN(c2ccccc2)C1)C1CCC(CO)CC1

nearest known ligand 0.55

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.55
DRD3 P35462 6/20 0.55
CNR1 P21554 1/20 0.53
USP30 Q70CQ3 1/20 0.50
ALDH1A1 P00352 2/20 0.47
EPHX2 P34913 2/20 0.44
NOTUM Q6P988 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HTR1A P08908 1/20 0.42
HTR2A P28223 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4010684 1.00 DRD2 (0.55) DRD2DRD3CNR1USP30ALDH1A1
SCHEMBL4004721 0.89 DRD2 (0.54) DRD2DRD3CNR1USP30ALDH1A1
SCHEMBL4004723 0.89 DRD2 (0.54) DRD2DRD3CNR1USP30ALDH1A1
SCHEMBL4552162 0.86 CNR1 (0.56) DRD2DRD3CNR1USP30ALDH1A1
SCHEMBL4004242 0.86 CNR1 (0.56) DRD2DRD3CNR1USP30ALDH1A1
SCHEMBL4006081 0.86 DRD2 (0.61) DRD2DRD3CNR1USP30ALDH1A1
SCHEMBL4006089 0.86 DRD2 (0.61) DRD2DRD3CNR1USP30ALDH1A1
SCHEMBL4148809 0.86 DRD2 (0.61) DRD2DRD3CNR1USP30ALDH1A1
SCHEMBL4007370 0.86 DRD2 (0.61) DRD2DRD3CNR1USP30ALDH1A1
SCHEMBL4007340 0.85 CNR1 (0.55) DRD2DRD3CNR1USP30ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP disclosed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP disclosed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO disclosed